AMENDMENT TO THE CLAIMS

The following listing of claims will replace all prior versions and listings of claims in the application:

1-25: (Canceled)

26. (Previously Presented) A method for treating hemorrhoid disease in a human in need thereof, comprising administering to said human an effective amount of a pharmaceutical composition, said composition consisting essentially of a thrombolytic protein selected from the group consisting of tissue-type plasminogen activator (t-PA), urokinase (u-PA), streptokinase (SK), or a combination thereof, wherein the pharmaceutical composition is administered rectally.

27. (Currently amended) The method according to claim 26, wherein the pharmaceutical composition ~~comprises~~ consists essentially of recombinant streptokinase and a pharmacologically acceptable diluent carrier or excipient.

28. (Previously Presented) The method according to claim 26, wherein the recombinant streptokinase has a concentration of 50,000 to 1,500,000 IU per gram of the pharmaceutical composition.

29. (Canceled)

30. (Canceled)

31. (Canceled)

32. (Cancelled)

33. (Previously Presented) The method according to claim 26, wherein the pharmaceutical composition is a suppository.

34. (New) A method for treating hemorrhoid disease in a human in need thereof, comprising administering to said human an effective amount of a pharmaceutical composition, said composition consisting essentially of a thrombolytic protein selected from the group consisting of tissue-type plasminogen activator (t-PA), urokinase (u-PA), streptokinase (SK), or a combination thereof, and ethylenediaminetetraacetic acid (EDTA) and sodium diclofenac, wherein the pharmaceutical composition is administered rectally.

35. (New) A method for treating hemorrhoid disease in a human in need thereof, comprising administering to said human an effective amount of a pharmaceutical composition, said composition consisting essentially of a thrombolytic protein selected from the group consisting of tissue-type plasminogen activator (t-PA), urokinase (u-PA), streptokinase (SK), or a combination thereof, and ethylenediaminetetraacetic acid (EDTA) and sodium salicylate, wherein the pharmaceutical composition is administered rectally.